

# Cancer risk in type 2 diabetes patients treated with sulfonylurea.

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Recruiting
<b>Health condition type</b>	-
<b>Study type</b>	Observational non invasive

## Summary

### ID

NL-OMON26303

### Source

NTR

### Brief title

ZODIAC-55

### Health condition

Type 2 diabetes, cancer, kanker.

## Sponsors and support

**Primary sponsor:** Diabetes Centre Isala

**Source(s) of monetary or material Support:** ZonMW

## Intervention

## Outcome measures

### Primary outcome

Within-sulfonylurea-class differences in obesity-related cancer risk (hazard ratio).

### Secondary outcome

Within-sulfonylurea-class differences in all cancer risk and site specific cancer risk of breast,

colorectal, bladder, advanced prostate cancer and lung cancer, expressed as hazard ratio.

## Study description

### Study objective

Patients with Type 2 diabetes have been shown to have an increased risk for developing cancer, especially obesity related cancers. There is some evidence that within the class of sulfonylureas there is a difference in cancer risk; gliclazide could be associated with a decreased cancer risk when compared to the other sulfonylureas.

### Study design

Hazard ratio will be calculated for a period up to 10 years.

### Intervention

Individual sulfonylurea treatment (gliclazide, glimepiride, tolbutamide, glibenclamide)

## Contacts

### Public

Dr. Spanjaardweg 11, 2e etage

Dennis Schrijnders  
Zwolle 8025 BT  
The Netherlands  
0031-38-4247763

### Scientific

Dr. Spanjaardweg 11, 2e etage

Dennis Schrijnders  
Zwolle 8025 BT  
The Netherlands  
0031-38-4247763

## Eligibility criteria

## Inclusion criteria

Type 2 diabetes patients treated with sulfonylureas

## Exclusion criteria

Type 2 diabetes patients treated with long-acting or mixed insulin before oral glucose lowering agents and those receiving insulin on top of sulfonylurea at study entry.

## Study design

### Design

Study type:	Observational non invasive
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Single blinded (masking used)
Control:	Active

### Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	30-01-2017
Enrollment:	0
Type:	Anticipated

## Ethics review

Positive opinion	
Date:	06-01-2017
Application type:	First submission

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
NTR-new	NL6035
NTR-old	NTR6166
Other	: ZODIAC-55, METC 13.0765

## Study results